Klaus Krebber

Title: Klaus Krebber: Innovator in Ligand-Binding Protein Selection

Introduction

Klaus Krebber is a notable inventor based in Zurich, Switzerland. He has made significant contributions to the field of protein engineering, particularly in the selection of ligand-binding proteins. His innovative methods have the potential to advance therapeutic applications and enhance our understanding of protein interactions.

Latest Patents

Krebber holds a patent for a "Method for in vivo selection of ligand-binding proteins." This application discloses a method and kit that enables the selection of proteins or other oligo- or polypeptides, collectively referred to as ligand-binding proteins (LBPs), which bind with high affinity to a target ligand or receptor. The method relies on the display of the LBP of interest on the surface of replicable genetic packages (RGPs) that are modified to be non-infective. Infectivity is restored to those RGPs displaying LBPs with high affinity for a target ligand or receptor by an infectivity mediating complex. This complex comprises the ligand or receptor covalently linked to a polypeptide that facilitates interaction between the RGP and a host cell. The method allows for the selection of substances with high affinity for a target from a large collection of variants.

Career Highlights

Klaus Krebber is associated with Morphosys Gesellschaft für Proteinoptimierung mbH, where he continues to work on innovative solutions in protein engineering. His expertise in the field has positioned him as a key figure in advancing the understanding of protein-ligand interactions.

Collaborations

Krebber has collaborated with notable colleagues, including Simon Moroney and Andreas Pluckthun. These partnerships have contributed to the development of groundbreaking methods in the selection of ligand-binding proteins.

Conclusion

Klaus Krebber's work in the field of ligand-binding proteins exemplifies the innovative spirit of modern science. His contributions have the potential to significantly impact therapeutic development and protein research.